BR112018071602A2 - compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase - Google Patents

compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase

Info

Publication number
BR112018071602A2
BR112018071602A2 BR112018071602-2A BR112018071602A BR112018071602A2 BR 112018071602 A2 BR112018071602 A2 BR 112018071602A2 BR 112018071602 A BR112018071602 A BR 112018071602A BR 112018071602 A2 BR112018071602 A2 BR 112018071602A2
Authority
BR
Brazil
Prior art keywords
dioxigenase
indolamine
tryptophan
inhibitors
compounds
Prior art date
Application number
BR112018071602-2A
Other languages
English (en)
Other versions
BR112018071602B1 (pt
Inventor
M. COWLEY Phillip
Ann Mcgowan Meredeth
J. Brown Thomas
Han Yongxin
Liu Kun
Pu Qinglin
Wise Alan
Zhang Hongjun
Zhou Hua
Original Assignee
Merck Sharp & Dohme Corp.
Iomet Pharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp., Iomet Pharma Ltd. filed Critical Merck Sharp & Dohme Corp.
Publication of BR112018071602A2 publication Critical patent/BR112018071602A2/pt
Publication of BR112018071602B1 publication Critical patent/BR112018071602B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

são divulgados aqui compostos de imidazopiridina substituídos de fórmula (i) que são inibidores das enzimas indolamina 2,3-dioxigenase (ido) e/ou triptofan-2,3-dioxigenase (tdo): (i). também são divulgados aqui os usos dos compostos no tratamento ou prevenção potencial de uma doença ou distúrbio associado a ido e/ou tdo. também são divulgadas aqui composições compreendendo estes compostos. são ainda divulgados aqui os usos das composições no tratamento ou prevenção potencial de uma doença ou distúrbio associado a ido e/ou tdo.
BR112018071602-2A 2016-04-29 2017-04-24 Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase BR112018071602B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329579P 2016-04-29 2016-04-29
US62/329,579 2016-04-29
PCT/US2017/029042 WO2017189386A1 (en) 2016-04-29 2017-04-24 Novel substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase

Publications (2)

Publication Number Publication Date
BR112018071602A2 true BR112018071602A2 (pt) 2019-02-12
BR112018071602B1 BR112018071602B1 (pt) 2024-02-27

Family

ID=60161057

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071602-2A BR112018071602B1 (pt) 2016-04-29 2017-04-24 Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase

Country Status (11)

Country Link
US (1) US11096930B2 (pt)
EP (1) EP3448522B1 (pt)
JP (1) JP6948345B2 (pt)
KR (1) KR102456521B1 (pt)
CN (1) CN109069873B (pt)
AU (1) AU2017257377B2 (pt)
BR (1) BR112018071602B1 (pt)
CA (1) CA3021589A1 (pt)
MX (1) MX2018013164A (pt)
RU (1) RU2741911C2 (pt)
WO (1) WO2017189386A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668880B1 (en) 2017-08-17 2021-10-06 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
JP7217279B2 (ja) 2018-01-15 2023-02-02 イドーシア ファーマシューティカルズ リミテッド インドールアミン ２，３－ジオキシゲナーゼ及び／又はトリプトファン ２，３－ジオキシゲナーゼの阻害剤
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
WO2019206800A1 (en) * 2018-04-24 2019-10-31 Phenex Discovery Verwaltungs-GmbH Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase
WO2019245890A1 (en) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US20220259212A1 (en) 2019-07-11 2022-08-18 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
KR102642194B1 (ko) 2019-10-11 2024-03-05 삼성전자주식회사 전압 컨트롤러 및 이를 포함하는 메모리 장치

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2008085302A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
JP5612860B2 (ja) * 2007-03-09 2014-10-22 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体
KR101783004B1 (ko) * 2008-07-08 2017-09-28 인사이트 홀딩스 코포레이션 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸
CN104114557B (zh) * 2012-02-21 2017-10-24 默克专利股份公司 作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪
SG10201707545XA (en) * 2013-03-14 2017-10-30 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
PE20151594A1 (es) * 2013-03-15 2015-11-19 Bristol Myers Squibb Co Inhibidores de indolamina 2-3 dioxigenasa
US9931347B2 (en) * 2013-12-03 2018-04-03 Iomet Pharma Ltd. Pharmaceutical compound
KR102518994B1 (ko) * 2014-05-28 2023-04-05 아스트라제네카 아베 Azd5363의 제조 방법 및 그에 사용되는 신규 중간체
GB201414730D0 (en) * 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
EP3207030A4 (en) * 2014-10-14 2018-06-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP6701214B2 (ja) 2014-11-03 2020-05-27 イオメット ファーマ リミテッド 医薬化合物
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound

Also Published As

Publication number Publication date
EP3448522A4 (en) 2019-11-27
CN109069873B (zh) 2021-07-20
MX2018013164A (es) 2019-06-24
WO2017189386A1 (en) 2017-11-02
AU2017257377B2 (en) 2022-06-23
CA3021589A1 (en) 2017-11-02
EP3448522A1 (en) 2019-03-06
KR102456521B1 (ko) 2022-10-20
KR20190003619A (ko) 2019-01-09
RU2741911C2 (ru) 2021-01-29
BR112018071602B1 (pt) 2024-02-27
US20200230117A1 (en) 2020-07-23
JP6948345B2 (ja) 2021-10-13
CN109069873A (zh) 2018-12-21
RU2018140732A (ru) 2020-05-29
RU2018140732A3 (pt) 2020-06-02
AU2017257377A1 (en) 2018-10-11
JP2019515923A (ja) 2019-06-13
EP3448522B1 (en) 2021-01-20
US11096930B2 (en) 2021-08-24

Similar Documents

Publication Publication Date Title
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
BR112019005595A2 (pt) compostos e métodos para modulação de ido e tdo, e indicações para os mesmos
BR112015032595A2 (pt) inibidores de ido
EA201891674A1 (ru) Ингибиторы лизилоксидаз, представляющие собой индольные и азаиндольные производные галогеналлиламина, и их применения
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
EA201790806A1 (ru) Иммунорегулирующие средства
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
EA201792047A1 (ru) Новые соединения
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
BR112016028255A2 (pt) agentes imunorreguladores
BR112014026703A2 (pt) inibidores de dna-pk
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
BR112018013820A2 (pt) análogos de egf(a) com substituintes de ácido graxo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: IOMET PHARMA LTD. (GB) ; MERCK SHARP AND DOHME LLC (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/04/2017, OBSERVADAS AS CONDICOES LEGAIS